Synthesis and in-vitro biological activity of macrocyclic urea Chk1 inhibitors

被引：12

作者：

Li, Gaoquan ^{[1
]}

Tao, Zhi-Fu ^{[1
]}

Tong, Yunsong ^{[1
]}

Przytulinska, Magdalena K. ^{[1
]}

Kovar, Peter ^{[1
]}

Merta, Philip ^{[1
]}

Chen, Zehan ^{[1
]}

Zhang, Haiying ^{[1
]}

Sowin, Thomas ^{[1
]}

Rosenberg, Saul H. ^{[1
]}

Lin, Nan-Horng ^{[1
]}

机构：

[1] Abbott Labs, Global Pharmaceut Res & Dev, Canc Res, Abbott Pk, IL 60064 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 23期

关键词：

macrocyclic urea; Chk1; inhibitor;

D O I：

10.1016/j.bmcl.2007.09.088

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A variety of macrocyclic urea compounds were prepared as potent Chk1 inhibitors by modifying the C5 position of the benzene ring of the macrocyclic urea with ether moieties, aliphatic carbon chains, amide and halides. Enzymatic activity less than 20 nM was observed in 29 of 40 compounds. Compounds 14, 46d, and 48j provided the best overall results in the cellular assays as they abrogated doxorubicin-induced cell cycle arrest (IC50 = 3.31, 3.08, and 3.13 mu M) and enhanced doxorubicin cytotoxicity (IC50 = 0.54, 1.27, and 0.96 mu M) while displaying no single agent activity, respectively. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：6499 / 6504

页数：6

共 50 条

[21] BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1
Li, Lemin
Wang, Linchen
Liu, Dian
Zhao, Yongchao
CELL DEATH DISCOVERY, 2023, 9 (01)
[22] mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
Koppenhafer, Stacia L.
Goss, Kelli L.
Terry, William W.
Gordon, David J.
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (12) : 2676 - 2688
[23] BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1
Lemin Li
Linchen Wang
Dian Liu
Yongchao Zhao
Cell Death Discovery, 9
[24] Docking-based virtual screening of Chk1 inhibitors
Li, Yan
Kim, Dong Joon
Bode, Ann M.
Dong, Zigang
CANCER RESEARCH, 2011, 71
[25] Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
Ma, Cynthia X.
Janetka, James W.
Piwnica-Worms, Helen
TRENDS IN MOLECULAR MEDICINE, 2011, 17 (02) : 88 - 96
[26] CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells
Grabauskiene, Svetlana
Bergeron, Edward J.
Chen, Guoan
Chang, Andrew C.
Lin, Jules
Thomas, Dafydd G.
Giordano, Thomas J.
Beer, David G.
Morgan, Meredith A.
Reddy, Rishindra M.
LUNG CANCER, 2013, 82 (03) : 477 - 484
[27] Synthesis and CHK1 inhibitory potency of Hymenialdisine analogues
Parmentier, Jean-Gilles
Portevin, Bernard
Golsteyn, Roy M.
Pierre, Alain
Hickman, John
Gloanec, Philippe
De Nanteuil, Guillaume
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (03) : 841 - 844
[28] Global Analysis of Phosphorylation of Tau by the Checkpoint Kinases Chk1 and Chk2 in vitro
Mendoza, Jhoana
Sekiya, Michiko
Taniguchi, Taizo
Iijima, Koichi M.
Wang, Rong
Ando, Kanae
JOURNAL OF PROTEOME RESEARCH, 2013, 12 (06) : 2654 - 2665
[29] CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy
McNeely, S.
Beckmann, R.
Lin, A. K. Bence
PHARMACOLOGY & THERAPEUTICS, 2014, 142 (01) : 1 - 10
[30] CHK1 Inhibitors in Combination Chemotherapy Thinking Beyond the Cell Cycle
Dent, Paul
Tang, Yong
Yacoub, Adly
Dai, Yun
Fisher, Paul B.
Grant, Steven
MOLECULAR INTERVENTIONS, 2011, 11 (02) : 133 - 140

← 1 2 3 4 5 →